3Analytics Is Teaching Safety Data to Speak Before It Shouts

The most consequential warning in healthcare may begin as a sentence nobody notices. It could sit in a medical journal, surface in a device complaint, arrive in a regulator's database or appear as a faint statistical imbalance among thousands of routine reports. Somewhere, a safety professional must connect it to the right product, test whether it is meaningful, document the reasoning and decide what happens next.

This is pharmacovigilance, the long watch that begins when medicines, vaccines and medical devices meet the uncontrolled mess of real life. It is necessary, technical and full of small queues. Search results wait to be screened. Duplicate articles wait to be removed. Complaint narratives wait for standardized codes. Regulatory updates wait to be routed to the right person. None of this resembles the cinematic version of artificial intelligence. That is precisely why 3Analytics is interesting.

Founded in Silicon Valley in January 2020 by physician and safety specialist Dr. Dharani Munirathinam, the company builds software for those queues. Its suite collects evidence, applies machine learning and natural-language processing, runs established safety statistics, and turns the result into a workflow a regulated team can inspect. The company is not trying to make the final medical judgment disappear. It is trying to make sure the evidence reaches that judgment sooner, cleaner and with its trail intact.

The useful question is not whether AI can read a complaint. It is whether the right human can review the right complaint before the queue wins.

A product line built around bottlenecks

3Analytics sells a set of connected but distinct products. Signals is the analytical center. It brings together safety data from public agencies, literature and internal systems, then supports both qualitative review and quantitative detection. Its toolkit includes more than 20 algorithms, from familiar disproportionality measures such as reporting odds ratio and proportional reporting ratio to regression, temporal association and population-specific analysis. Dashboards let teams follow a signal through review, validation and reporting.

BioMed attacks a different kind of overload. Drug-safety teams must monitor biomedical publications for case reports and new risk information, often across languages and databases. Search is only the opening move. Results must be collected, de-duplicated, screened, classified and prepared for downstream safety systems. BioMed automates much of that movement and supports E2B(R3)-aligned output, the structured format used to exchange individual case safety reports.

RegIntel watches the rulebook instead of the evidence. 3Analytics says the product covers more than 100 countries, more than 1,000 links and over 200 regulatory documents across drugs, biologics, devices and vaccines. Its assistant, Luna, answers questions against that organized repository. The important word is organized. A regulatory answer must be connected to a jurisdiction, product type and reporting stage. Fluency without provenance is of limited use when an inspection begins.

Seconds matter, but context matters more

The company's sharpest example is medical-device complaint coding. Manufacturers receive free-text accounts of device problems, then specialists map the narrative to codes maintained by the International Medical Device Regulators Forum. The work demands context. A loose keyword match can confuse what happened to a device with what happened to a patient, or miss that one complaint contains several allegations.

In March 2025, quality-management software provider AssurX announced an alliance that embeds 3Analytics' coding capability inside AssurX EQMS. The partners say the integrated tool can suggest six relevant annex codes from context and reduce a task that commonly took about 15 minutes to a matter of seconds. They also claim cost reductions of up to 72 percent. Those are vendor-reported results, not a universal benchmark, but the structure of the use case is telling: repetitive expert labor, controlled vocabularies, frequent rule updates and an existing system where a reviewer can accept or correct the result.

Another partnership places 3Analytics inside a larger service wrapper. Tech Mahindra's Robovigilance offering combines the startup's AI components with the global consultancy's cloud, automation and life-sciences delivery capabilities. For 3Analytics, that is distribution and enterprise credibility. For a buyer, it offers one path to deploy specialist software without asking a small vendor to carry every integration and transformation task alone.

Who buys it - and why now

The natural buyers are pharmacovigilance, medical-device complaint, regulatory-affairs, quality and epidemiology teams. They work inside pharmaceutical companies, biotechs, vaccine makers, device manufacturers and cosmetics businesses. Public-health agencies and NGOs are another flank. 3Analytics says it has worked with JHPIEGO, the Johns Hopkins public-health affiliate, and was shortlisted by the World Health Organization for active vaccine-safety surveillance.

These customers face the same uncomfortable arithmetic. The volume of available evidence keeps growing, but experienced reviewers do not multiply on demand. Data lives in different formats and languages. Regulations change by country. A missed signal carries clinical and reputational risk; an undisciplined false alarm consumes expert time and can send a team down the wrong corridor. Software must therefore do two apparently opposing things: move faster and preserve scrutiny.

The business model follows familiar enterprise-software lines. 3Analytics hosts products on the cloud, sells through demos, integrates with customers' existing safety and quality systems, and provides tailored development for public-health programs. Prices are not published. That makes it a vertical SaaS company with a services edge - software at the center, domain implementation around it, and partnerships that can carry the products into broader accounts.

Small company, crowded room

3Analytics competes in a market with formidable incumbents. Oracle Argus, Veeva Vault Safety, IQVIA, ArisGlobal and Ennov offer established pharmacovigilance systems. Specialist vendors cover literature, signals or regulatory intelligence. Many large drugmakers also have deeply customized internal workflows. Buyers do not replace that infrastructure casually.

The company's answer is focus and modularity. It can integrate a coding engine into AssurX rather than insist that a device maker replace its quality system. It can augment Tech Mahindra's service rather than build a global consultancy. And it can put domain experts - physicians, safety leaders, epidemiologists and regulatory specialists - alongside engineers. In regulated software, knowing why a field exists can matter as much as predicting what goes in it.

That multidisciplinary posture is visible in the leadership team. Munirathinam spent more than 15 years in drug and device safety roles. Product leaders bring backgrounds in pharmacovigilance, clinical research and post-market surveillance. Engineering and AI staff work beside an epidemiologist. The culture described publicly is science-led and patient-safety oriented, although its practical test is more prosaic: whether product, quality and engineering can agree on what the software must record when an algorithm is wrong.

From one complaint to 63,032 children

The company's public-health work expands the scale of the story. In a Madhya Pradesh immunization pilot, 3Analytics says its systems identified 63,032 zero-dose children, reached 29,944 through advocacy and community engagement, and helped 774 receive vaccinations. The large drop between identification and vaccination is not an embarrassment to hide. It reveals the shape of the actual problem. Analytics can find a family; it cannot create a road, maintain a cold chain or manufacture trust.

That is also a useful boundary for the entire company. A model can prioritize a paper, calculate a disproportionality score, suggest a complaint code or flag a district. The result still enters an organization full of human constraints. 3Analytics is most credible when its software acknowledges that fact and becomes part of the handoff: alerts, queues, review states, dashboards, audit records and integrations.

The company remains privately held and relatively small. Its LinkedIn page places it in the 51-to-200 employee band; supplied company data puts the team near 55 and records a $470,000 seed round in 2021. Revenue and valuation are not public. The more revealing indicators are product depth and the partners willing to place its technology in front of regulated customers.

Healthcare AI will continue to generate grand promises. The work at 3Analytics offers a more grounded measure: fewer hours lost to duplicate evidence, faster access to a changing requirement, a complaint coded consistently, a weak signal moved to an expert's desk. Safety rarely arrives as a single revelation. More often, it is assembled from hundreds of careful, traceable decisions. The startup is building the machinery between them.